from the clinically available prostheses, living heart valves, made with and by the cells of the patient, are endowed with the capability of growing and remodeling, and therefore, with the potential of lasting for a whole lifetime. This eliminates the need for pharmaceutical therapies normally associated with mechanical heart valves and for multiple interventions due to structural degeneration and calcification, as happens with biological prostheses.
Heart valve tissue engineering started with the classical bioreactor-based approach where autologous cells are seeded onto a polymeric scaffold and are conditioned in vitro in a bioreactor under biochemical and mechanical stimulation to guide the tissue formation. Once adequate mechanical properties are achieved, the construct is implanted. Historically, TEHVs reproduced the native heart valve geometry and were meant for surgical implantation. Single leaflets to be individually sutured orthotopically were also proposed. Different materials and fabrication methods have been proposed to create TEHVs. Natural and synthetic polymers have been processed with a variety of fabrication techniques, including molding, fiber-forming techniques (e.g., electrospinning, jet spinning, melt-electrowriting), salt leaching, and additive manufacture. Following the clinical advancements, TEHVs have been also developed for minimally invasive implantation, and the shape of the constructs has evolved to a tubular geometry, which is easier to produce and more robust.
In the last few years, the field of heart valve tissue engineering has witnessed a significant shift toward in situ tissue engineering. This approach proposes the implantation of cell-free scaffolds that elicit a host reaction, ideally toward an endogenous healing process, ultimately resulting in the formation of autologous tissue that is mechanically and biologically equivalent to the healthy native one. This approach simplifies significantly the fabrication phase, by eliminating the bioreactor conditioning, the logistic, by providing off-the-shelf implants, and the regulatory aspects. However, it poses important issues with respect to the capability of the implant to steer the host reaction away from a chronic inflammation. To this end, the temporal polarization of the macrophages from a pro-inflammatory to an anti-inflammatory phenotype is believed to be of key importance. The microenvironment plays a pivotal role in the immunoresponse to the implant, in a complex interplay of many parameters, including the scaffold's structure (e.g., porosity, fiber diameter), the mechanical properties, the (bio)chemical composition, and the mechanical forces acting on the construct. A strategy to guide the host reaction is by pre-operatively seeding the implant with autologous cells (e.g., bone marrow mononuclear cells 
